Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients

Abstract There is currently a critical need to determine the efficacy of SARS-CoV-2 vaccination for immunocompromised patients. In this study, we determined the neutralizing antibody response in 160 cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and va...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cong Zeng, John P. Evans, Sarah Reisinger, Jennifer Woyach, Christina Liscynesky, Zeinab El Boghdadly, Mark P. Rubinstein, Karthik Chakravarthy, Linda Saif, Eugene M. Oltz, Richard J. Gumina, Peter G. Shields, Zihai Li, Shan-Lu Liu
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Biotechnology TP248.13-248.65 Biology (General) QH301-705.5 Biochemistry QD415-436
Acceso en línea:	https://doaj.org/article/b0b75e1c41084268a96830ebeb2c2906
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b0b75e1c41084268a96830ebeb2c2906
record_format	dspace
spelling	oai:doaj.org-article:b0b75e1c41084268a96830ebeb2c29062021-11-28T12:29:00ZImpaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients10.1186/s13578-021-00713-22045-3701https://doaj.org/article/b0b75e1c41084268a96830ebeb2c29062021-11-01T00:00:00Zhttps://doi.org/10.1186/s13578-021-00713-2https://doaj.org/toc/2045-3701Abstract There is currently a critical need to determine the efficacy of SARS-CoV-2 vaccination for immunocompromised patients. In this study, we determined the neutralizing antibody response in 160 cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non-Hodgkin’s lymphomas (NHL), after they received two doses of mRNA vaccines. Serum from 46 mRNA vaccinated health care workers (HCWs) served as healthy controls. We discovered that (1) cancer patients exhibited reduced neutralizing antibody titer (NT50) compared to HCWs; (2) CLL and NHL patients exhibited the lowest NT50 levels, with 50-60% of them below the detection limit; (3) mean NT50 levels in patients with CLL and NHL was ~2.6 fold lower than those with solid tumors; and (4) cancer patients who received anti-B cell therapy exhibited significantly reduced NT50 levels. Our results demonstrate an urgent need for novel immunization strategies for cancer patients against SARS-CoV-2, particularly those with hematological cancers and those on anti-B cell therapies.Cong ZengJohn P. EvansSarah ReisingerJennifer WoyachChristina LiscyneskyZeinab El BoghdadlyMark P. RubinsteinKarthik ChakravarthyLinda SaifEugene M. OltzRichard J. GuminaPeter G. ShieldsZihai LiShan-Lu LiuBMCarticleBiotechnologyTP248.13-248.65Biology (General)QH301-705.5BiochemistryQD415-436ENCell & Bioscience, Vol 11, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Biotechnology TP248.13-248.65 Biology (General) QH301-705.5 Biochemistry QD415-436
spellingShingle	Biotechnology TP248.13-248.65 Biology (General) QH301-705.5 Biochemistry QD415-436 Cong Zeng John P. Evans Sarah Reisinger Jennifer Woyach Christina Liscynesky Zeinab El Boghdadly Mark P. Rubinstein Karthik Chakravarthy Linda Saif Eugene M. Oltz Richard J. Gumina Peter G. Shields Zihai Li Shan-Lu Liu Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients
description	Abstract There is currently a critical need to determine the efficacy of SARS-CoV-2 vaccination for immunocompromised patients. In this study, we determined the neutralizing antibody response in 160 cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non-Hodgkin’s lymphomas (NHL), after they received two doses of mRNA vaccines. Serum from 46 mRNA vaccinated health care workers (HCWs) served as healthy controls. We discovered that (1) cancer patients exhibited reduced neutralizing antibody titer (NT50) compared to HCWs; (2) CLL and NHL patients exhibited the lowest NT50 levels, with 50-60% of them below the detection limit; (3) mean NT50 levels in patients with CLL and NHL was ~2.6 fold lower than those with solid tumors; and (4) cancer patients who received anti-B cell therapy exhibited significantly reduced NT50 levels. Our results demonstrate an urgent need for novel immunization strategies for cancer patients against SARS-CoV-2, particularly those with hematological cancers and those on anti-B cell therapies.
format	article
author	Cong Zeng John P. Evans Sarah Reisinger Jennifer Woyach Christina Liscynesky Zeinab El Boghdadly Mark P. Rubinstein Karthik Chakravarthy Linda Saif Eugene M. Oltz Richard J. Gumina Peter G. Shields Zihai Li Shan-Lu Liu
author_facet	Cong Zeng John P. Evans Sarah Reisinger Jennifer Woyach Christina Liscynesky Zeinab El Boghdadly Mark P. Rubinstein Karthik Chakravarthy Linda Saif Eugene M. Oltz Richard J. Gumina Peter G. Shields Zihai Li Shan-Lu Liu
author_sort	Cong Zeng
title	Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients
title_short	Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients
title_full	Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients
title_fullStr	Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients
title_full_unstemmed	Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients
title_sort	impaired neutralizing antibody response to covid-19 mrna vaccines in cancer patients
publisher	BMC
publishDate	2021
url	https://doaj.org/article/b0b75e1c41084268a96830ebeb2c2906
work_keys_str_mv	AT congzeng impairedneutralizingantibodyresponsetocovid19mrnavaccinesincancerpatients AT johnpevans impairedneutralizingantibodyresponsetocovid19mrnavaccinesincancerpatients AT sarahreisinger impairedneutralizingantibodyresponsetocovid19mrnavaccinesincancerpatients AT jenniferwoyach impairedneutralizingantibodyresponsetocovid19mrnavaccinesincancerpatients AT christinaliscynesky impairedneutralizingantibodyresponsetocovid19mrnavaccinesincancerpatients AT zeinabelboghdadly impairedneutralizingantibodyresponsetocovid19mrnavaccinesincancerpatients AT markprubinstein impairedneutralizingantibodyresponsetocovid19mrnavaccinesincancerpatients AT karthikchakravarthy impairedneutralizingantibodyresponsetocovid19mrnavaccinesincancerpatients AT lindasaif impairedneutralizingantibodyresponsetocovid19mrnavaccinesincancerpatients AT eugenemoltz impairedneutralizingantibodyresponsetocovid19mrnavaccinesincancerpatients AT richardjgumina impairedneutralizingantibodyresponsetocovid19mrnavaccinesincancerpatients AT petergshields impairedneutralizingantibodyresponsetocovid19mrnavaccinesincancerpatients AT zihaili impairedneutralizingantibodyresponsetocovid19mrnavaccinesincancerpatients AT shanluliu impairedneutralizingantibodyresponsetocovid19mrnavaccinesincancerpatients
_version_	1718407976777154560

Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients

Ejemplares similares